CD8A and neoplasm: Although we observed no impact of VSVΔ51+T-DM1 on the activation status of CD8+ T-cells in tumours, TdLN, or spleens (Figure S4D), our analyses revealed an average 2-fold increase in activated CD44hi, CD25+, or CD69+ tumour-infiltrating CD4+ T-cells in the same treatment group (Figures 7I, S5F, G), relative to PBS or monotherapies.